Sawai Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sawai Pharmaceutical Co., Ltd.
Who’s Hired? New Mithra CEO Mulls Selling Generics Business
Mithra’s new CEO has immediately signaled a potential sale for the firm’s generics business as it looks to focus on branded assets in women’s health. Meanwhile, Sawai has reorganized its management team, the longtime chair of Viatris is moving on to another role, and a former AAM vice-president has joined Sandoz.
Novo Nordisk Teams With Aspect Biosystems On Diabetes Cell Therapy
Aspect says its bioprinted tissue therapeutics include immune-resistant encapsulation, which Novo Nordisk hopes will offer a safer approach to type 1 diabetes cell therapy.
As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics
As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form of benzylpenicillin injection. But the country has approved the drug only recently and in answer to a push from doctors on the front line.
Is Sawai Heading For A Cash Creation Crisis?
Three quarters of the way through its financial year, Sawai has half as much cash on its balance sheet as it did at the same stage in 2021/22, as the Japanese firm continues to be dogged by lower government-mandated prices and higher costs at home.
- Generic Drugs
- Other Names / Subsidiaries
- Cambridge Biotechnology Ltd (CBT)
- Minster Pharmaceuticals
- Proximagen Group
- Upsher-Smith Laboratories Inc.
- Medisa Shinyaku Inc. and Kaken Shoyaku Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.